Vendor strategies in the global multiple sclerosis drugs market

The global multiple sclerosis drugs market is expected to grow at a CAGR of 5.86% during the forecast period. Major vendors in the global multiple sclerosis drugs market include Bayer AG, Biogen, Merck KGaA, Novartis AG, and Sanofi, among others.

Vendors are focusing on strategies such as new product launches to enhance their presence in the market. For instance, Bayer AG, in December 2017, STIVARGA was approved in China by the China FDA for the second-line systemic treatment of liver cancer. Biogen, in June 2017, the European Commission granted marketing authorization for SPINRAZA for the treatment of SMA in pediatric and adult patients in Europe.

Request for: Free Sample Report

Merck KGaA, in November 2018, the company launched BioContinuum, a new platform for advancing its biotherapeutic drug manufacturing. Sanofi, in March 2017, Sanofi announced that FDA has approved DUPIXENT, the only biologic medicine for the treatment of adults with moderate-to-severe atopic dermatitis. Hence, the rising number of new product launches is expected to augment the growth of the global multiple sclerosis drugs market during the forecast period.